Decentralisation of multidrug-resistant-tuberculosis care and management [letter] by Cox, H & Ford, N
Comment
www.thelancet.com/infection   Published online June 4, 2013   http://dx.doi.org/10.1016/S1473-3099(13)70151-8 1
Decentralisation of multidrug-resistant-tuberculosis care 
and management
Multidrug-resistant (MDR) tuberculosis is an 
important medical and public health challenge, 
aﬄ  icting an estimated 500 000 new patients each 
year. Recent progress in the development of new 
molecular diagnostic techniques1 and the ﬁ rst new 
antituberculosis drug registration in almost 40 years2 
provide reasons for optimism, but still, globally, less 
than 10% of individuals with MDR-tuberculosis receive 
treatment of known quality. 
Country data for detection and enrolment onto 
treatment reported to WHO over the past 3 years 
paint a varied picture of progress.3 Some high burden 
countries report steady increases in the numbers of 
patients treated over the past 3 years, notably India, 
Russia, and South Africa. However, less than a quarter 
of the countries providing complete data showed a 
linear increase in case detection, and less than half 
showed a year-on-year increase in the numbers of 
patients enrolled onto treatment. No country that 
treated more than 500 patients achieved a treatment 
success rate of greater than 55%. There has been 
progress in places, but not nearly enough.
Impediments towards universal access to MDR-
tuberculosis treatment are many, ranging from 
insuﬃ  cient donor funding to poor laboratory 
diagnostic capacity and health system challenges, 
including the need to encourage ambulatory care 
models.4 This last point is crucial, because although 
advances in diagnostics and improved treatment 
regimens will go a long way to improving access, 
the models of care in which such technologies are 
delivered will strongly aﬀ ect patient access and 
retention in care. 
Historically, MDR-tuberculosis treatment has been 
provided through small, individualised programmes 
with specialist clinical support.5 Such models of care 
might work where patient numbers are small, but 
in settings like South Africa and Russia, which both 
detected more than 10 000 cases in 2011 alone, 
specialised, centralised programmes are unlikely to 
meet the need. Moreover, larger MDR-tuberculosis 
treatment programmes are associated with poorer rates 
of retention in care.6 
Increased eﬀ orts in global tuberculosis control have 
resulted in strong basic tuberculosis programmes in 
many settings that have developed local systems for 
supporting patients on treatment for tuberculosis and 
ensuring adherence. Integration of MDR-tuberculosis 
care and management into routine tuberculosis 
programmes in such settings is feasible and allows 
patients with MDR-resistant tuberculosis to receive 
treatment close to where they live. 
There is increasing evidence from several large-scale 
MDR-tuberculosis programmes of improved access 
to care and management through decentralisation, 
without compromising treatment outcomes,7–10 
including programmes that have task shifted initiation 
of MDR-tuberculosis treatment to trained nurses.11 
Decentralisation has been a crucial strategy for 
expanding access to treatment for HIV and has been 
associated with better patient outcomes than with 
hospital-managed care, mainly due to improved 
retention;12,13 there is a broad consensus that to improve 
early health-seeking behaviour, promote adherence to 
medication, and minimise defaulting, HIV care is best 
provided as close as possible to the patient’s home and 
community. These lessons for patient support are clearly 
applicable to MDR-tuberculosis because default rates 
from care commonly exceed 20%.6 
One concern about decentralising MDR-tuberculosis 
care is the potential increased risk of community 
transmission, but in most high-burden settings, the 
MDR-tuberculosis epidemic is driven primarily by 
direct transmission of MDR-tuberculosis strains. The 
low proportion of estimated cases that are treated 
appropriately means that most transmission is occurring 
among undiagnosed and untreated cases. Therefore, 
eﬀ orts to reduce transmission should be directed at 
diagnosing and treating as many cases as possible and as 
early as possible.14
After decades of neglect, much needed improvements 
in diagnostics and therapeutics are becoming 
available. However, their impact will be small without 
parallel eﬀ orts to improve the service delivery model. 
Decentralisation is likely to oﬀ er the best opportunity 
for early initiation of treatment at the scale required, 
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reserving hospital resources to manage the small 
percentage of patients who require admission on clinical 
grounds and potentially for those in whom the drug 
resistance proﬁ le means few treatment options. 
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